← Back to Clinical Trials
Recruiting NCT06636747

High Resolution Diffusion Weighted Imaging in Prostate

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Prostate Cancer
Sponsor The First Affiliated Hospital with Nanjing Medical University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 500
Sex MALE
Min Age 55 Years
Max Age N/A
Start Date 2023-08-01
Completion 2025-07-31

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

hrDWI might be an alternative to cDWI for the prostate imaging. 1. increase the signal-to-noise ratio and contrast-to-noise ratio, yielding high-fidelity images with less noise in general 2. improve the diagnostic accuracy of PCa in particular than conventional DWI

Eligibility Criteria

Inclusion Criteria: 1. Patients who underwent standard MR scanning including T2WI, cDWI , hrDWI and respective calculated apparent diffusion coefficient (ADC) maps; 2. Complete clinical information. Exclusion Criteria: Men were excluded if they were using 5-alpha-reductase inhibitors at time of examination or has used such during the previous six months; or if they had a previous history of prostatic biopsy, prostatic surgery, or treatment for PCa

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}